Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Sees Large Growth in Short Interest

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the recipient of a large increase in short interest in the month of February. As of February 27th, there was short interest totaling 1,878 shares, an increase of 190.3% from the February 12th total of 647 shares. Based on an average trading volume of 32,271 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.1% of the shares of the company are sold short. Currently, 0.1% of the shares of the company are sold short. Based on an average trading volume of 32,271 shares, the days-to-cover ratio is presently 0.1 days.

Bolt Biotherapeutics Stock Performance

Shares of NASDAQ BOLT opened at $4.26 on Wednesday. Bolt Biotherapeutics has a 1 year low of $4.01 and a 1 year high of $9.66. The firm has a market cap of $8.18 million, a P/E ratio of -0.19 and a beta of 0.94. The stock has a fifty day moving average price of $5.49 and a two-hundred day moving average price of $5.38. The company has a debt-to-equity ratio of 0.65, a quick ratio of 3.57 and a current ratio of 3.57.

Analysts Set New Price Targets

A number of research analysts have issued reports on BOLT shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research report on Wednesday, January 21st. Zacks Research lowered Bolt Biotherapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, November 20th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Bolt Biotherapeutics currently has an average rating of “Hold” and an average price target of $34.00.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Renaissance Technologies LLC raised its position in Bolt Biotherapeutics by 92.2% in the fourth quarter. Renaissance Technologies LLC now owns 55,025 shares of the company’s stock worth $301,000 after acquiring an additional 26,400 shares in the last quarter. T3 Companies LLC bought a new position in shares of Bolt Biotherapeutics during the 4th quarter valued at about $208,000. Nano Cap New Millennium Growth Fund L P acquired a new position in shares of Bolt Biotherapeutics in the 4th quarter worth approximately $112,000. Susquehanna International Group LLP acquired a new position in shares of Bolt Biotherapeutics in the 3rd quarter worth approximately $89,000. Finally, Shay Capital LLC bought a new stake in shares of Bolt Biotherapeutics in the 3rd quarter worth approximately $85,000. 86.70% of the stock is owned by institutional investors and hedge funds.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.